Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.7Last Year’s EPS
0.46Same Quarter Last Year
Strong Buy
Based on 24 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: 4.88%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call for BioMarin highlighted strong financial growth and strategic advancements, particularly in VOXZOGO's expansion and enzyme therapy sales. Despite some expected reductions in growth rates for certain enzyme products and increased SG&A expenses, the overall sentiment remains positive due to strong revenue growth, expanded profitability, and promising future outlook.Company Guidance
During BioMarin Pharmaceuticals' fourth quarter 2024 conference call, the company reported record growth and profitability, exceeding market expectations across key financial metrics. BioMarin's full-year 2024 revenue grew by 18% to $2.85 billion, with a 16% year-over-year increase in the fourth quarter to $747 million. The company's non-GAAP operating margin expanded by over 900 basis points, reaching 28.6% for the year, and non-GAAP diluted earnings per share saw a 69% increase. BioMarin's operating cash flow also rose significantly, totaling $573 million for 2024, indicating a 260% increase from the previous year. The company expects a 10% revenue growth in 2025, targeting revenues between $3.1 billion and $3.2 billion, with strong contributions from VOXZOGO, which grew by 56% year-over-year, and enzyme therapies approaching $2 billion in annual revenues. BioMarin aims for a high single-digit CAGR in its enzyme therapy business and plans to achieve a 40% non-GAAP operating margin next year, with further revenue growth projected to reach $4 billion by 2027.Record Growth and Profitability
BioMarin's full-year 2024 results exceeded market expectations with an 18% year-over-year top-line growth. Non-GAAP operating margin expanded over 900 basis points, and non-GAAP diluted earnings per share increased by 69%.
VOXZOGO Expansion
VOXZOGO for achondroplasia saw a 56% year-over-year growth, with strong demand globally, contributing significantly to BioMarin's growth. The company plans to expand its use into hypochondroplasia by 2027.
Strong Enzyme Therapy Sales
The enzyme therapy business totaled over $1.9 billion for 2024, a 12% increase from 2023, with consistent growth across BioMarin's marketed brands.
Positive Financial Outlook for 2025
BioMarin expects between $3.1 billion and $3.2 billion in total revenue for 2025, representing a 10% growth compared to 2024, and plans to achieve a 40% non-GAAP operating margin next year.
Strong Operating Cash Flow
BioMarin generated $573 million of operating cash flow in 2024, a 260% increase over 2023, putting the company on track to achieve more than $1.25 billion in operating cash flow by 2027.
---
BMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $65.61 | $68.73 | +4.76% |
| Oct 29, 2024 | $69.91 | $66.68 | -4.62% |
| Aug 05, 2024 | $80.47 | $86.87 | +7.95% |
| Apr 24, 2024 | $91.20 | $82.17 | -9.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioMarin Pharmaceutical (BMRN) report earnings?
BioMarin Pharmaceutical (BMRN) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is BioMarin Pharmaceutical (BMRN) earnings time?
BioMarin Pharmaceutical (BMRN) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMRN EPS forecast?
BMRN EPS forecast for the fiscal quarter 2025 (Q1) is 0.7.
---
